Tingqing Wu

Ms. Tingqing Wu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
ATAnjan Tibrewala
Anjan Tibrewala
SCSarah Chuzi
Sarah Chuzi
TWTingqing Wu
Tingqing Wu
ABAbigail Baldridge
Abigail Baldridge
RHRebecca Harap
Rebecca Harap
JWJane E. Wilcox
Jane E. Wilcox
BACKGROUND: In October 2018, the US heart transplant (HT) allocation system was revised giving patients with left ventricular assist device (LVAD) intermediate priority status. Few studies have examined the impact of this policy change on outcomes among patients with LVAD. We sought to determine how the allocation change impacted waitlist and posttransplant mortality in patients with LVAD. METHODS: We retrospectively assessed the United Network for Organ Sharing registry for patients with LVAD who were listed for or underwent HT between October 2016 and October 2021. We evaluated waitlist mortality using competing risks analysis and a multivariable Fine-Gray model, and posttransplant mortality using Kaplan-Meier survival analysis and a multivariate proportional hazards model. RESULTS: We analyzed data from 3835 patients with LVAD listed for HT and 3486 patients with LVAD who underwent HT during the study period. Listing for HT preallocation change was significantly associated with an increased risk of waitlist mortality (Gray P =0.0058) compared with postallocation change. After adjustment for covariates, mortality differences by listing era were attenuated, but LVAD brand was significantly associated with waitlist mortality (HM3 versus HMII; hazard ratio, 0.38 [95% CI, 0.21–0.69]; P =0.002; HVAD versus HMII; hazard ratio, 0.79 [95% CI, 0.48–1.30]; P =0.36; overall P =0.004). In contrast, HT postallocation change was associated with increased posttransplant mortality (log-rank P =0.0172) compared with preallocation change. In a multivariable analysis, the association with posttransplant mortality between transplant eras was attenuated, but ischemic time (hazard ratio, 1.16 [95% CI, 1.07–1.26]; P <0.001) and status at time of HT (Status 1–3 versus 4; hazard ratio, 1.29 [95% CI, 1.04–1.61]; P =0.02) were significantly associated with posttransplant mortality. CONCLUSIONS: Among patients with LVAD, lower waitlist mortality postallocation change was likely driven by improved LVAD technology. Higher posttransplant mortality following the allocation change was largely attributable to longer ischemic times and patient acuity.

1 August 2020 in Journal of the National Medical Association
Verified
Journal Article
Closed access
CLChien-Ching Li
Chien-Ching Li
AMAlicia K. Matthews
Alicia K. Matthews
TWTingqing Wu
Tingqing Wu

22 April 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MPM.G. Petty
M.G. Petty
TWTingqing Wu
Tingqing Wu
AAA.C. Andrei
A.C. Andrei
ABA. Baldridge
A. Baldridge
AWA. Warzecha
A. Warzecha
KGK.L. Grady
K.L. Grady

28 November 2022 in ASAIO Journal
Verified
Journal Article
Closed access
ATAnjan Tibrewala
Anjan Tibrewala
RWRamsey M. Wehbe
Ramsey M. Wehbe
TWTingqing Wu
Tingqing Wu
RHRebecca Harap
Rebecca Harap
KGKambiz Ghafourian
Kambiz Ghafourian
JRJonathan D. Rich
Jonathan D. Rich
Serum sodium is an established prognostic marker in heart failure (HF) patients and is associated with an increased risk of morbidity and mortality. We sought to study the prognostic value of serum sodium in left ventricular assist device (LVAD) patients and whether hyponatremia reflects worsening HF or an alternative mechanism. We identified HF patients that underwent LVAD implantation between 2008 and 2019. Hyponatremia was defined as Na ≤134 mEq/L at 3 months after implantation. We assessed for differences in hyponatremia before and after LVAD implantation. We also evaluated the association of hyponatremia with all-cause mortality and recurrent HF hospitalizations. There were 342 eligible LVAD patients with a sodium value at 3 months. Among them, there was a significant improvement in serum sodium after LVAD implantation compared to preoperatively (137.2 vs. 134.7 mEq/L, P < 0.0001). Patients with and without hyponatremia had no significant differences in echocardiographic and hemodynamic measurements. In a multivariate analysis, hyponatremia was associated with a markedly increased risk of all-cause mortality (HR 3.69, 95% CI, 1.93–7.05, P < 0.001) when accounting for age, gender, co-morbidities, use of loop diuretics, and B-type natriuretic peptide levels. Hyponatremia was also significantly associated with recurrent HF hospitalizations (HR 2.11, 95% CI, 1.02–4.37, P = 0.04). Hyponatremia in LVAD patients is associated with significantly higher risk of all-cause mortality and recurrent HF hospitalizations. Hyponatremia may be a marker of ongoing neurohormonal activation that is more sensitive than other lab values, echocardiography parameters, and hemodynamic measurements.

1 August 2023 in Circulation: Heart Failure
Verified
Journal Article
Closed access
SCSarah Chuzi
Sarah Chuzi
JWJane E. Wilcox
Jane E. Wilcox
AKAndrew Kao
Andrew Kao
JSJohn A. Spertus
John A. Spertus
EHEileen Hsich
Eileen Hsich
KGKathleen L. Grady
Kathleen L. Grady
BACKGROUND: Information about health-related quality of life (HRQOL) among caregivers of older patients with heart failure who receive heart transplantation (HT) and mechanical circulatory support (MCS) is sparse. We describe differences and factors associated with change in HRQOL before and early post-surgery among caregivers of older heart failure patients who underwent 3 surgical therapies: HT with pretransplant MCS (HT MCS), HT without pretransplant MCS (HT non-MCS), and long-term MCS. METHODS: Caregivers of older patients (60–80 years) from 13 US sites completed the EQ-5D-3 L visual analog scale (0 [worst]–100 [best] imaginable health state) and dimensions before and 3 and 6 months post-surgery. Analyses included linear regression, t tests, and nonparametric tests. RESULTS: Among 227 caregivers (HT MCS=54, HT non-MCS=76, long-term MCS=97; median age 62.7 years, 30% male, 84% White, 83% spouse/partner), EQ-5D visual analog scale scores were high before (84.8±14.1) and at 3 (84.7±13.0) and 6 (83.9±14.7) months post-surgery, without significant differences among groups or changes over time. Patient pulmonary hypertension presurgery (β=−13.72 [95% CI, −21.07 to −6.36]; P <0.001) and arrhythmia from 3 to 6 months post-operatively (β=−14.22 [95% CI, −27.41 to −1.02]; P =0.035) were associated with the largest decrements in caregiver HRQOL; patient marital/partner status (β=6.21 [95% CI, 1.34–11.08]; P =0.013) and presurgery coronary disease (β=8.98 [95% CI, 4.07–13.89]; P <0.001) were associated with the largest improvements. CONCLUSIONS: Caregivers of older patients undergoing heart failure surgeries reported overall high HRQOL before and early post-surgery. Understanding factors associated with caregiver HRQOL may inform decision-making and support needs. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02568930.

28 December 2021 in ASAIO Journal
Verified
Journal Article
Closed access
SRScott Roberts
Scott Roberts
HNHannah H. Nam
Hannah H. Nam
RKRebecca N. Kumar
Rebecca N. Kumar
TWTingqing Wu
Tingqing Wu
RHRebecca S. Harap
Rebecca S. Harap
VSValentina Stosor
Valentina Stosor
Infection is a leading cause of morbidity and mortality in patients with ventricular assist devices (VAD). The impact of colonization with multidrug-resistant organisms (MDRO) on outcomes in this cohort is unknown. Patients on VAD support from July 2008 to September 2018 at a single site were evaluated for MDRO colonization after implantation. MDROs included methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus species, and extended-spectrum beta-lactamase producing gram-negative bacteria. 378 patients with 433 VADs were included. 42.6% (n = 161) of patients were colonized with an MDRO throughout the duration of VAD support. Eighty-two VAD infections occurred, 74.4% (n = 61) of whom were MDRO colonized before infection. MDRO colonization was associated with an increased risk of a subsequent VAD infection (hazard ratio 3.704, p < 0.001). MDRO colonization is common after VAD implantation and is associated with future VAD infections. Further study is needed to determine best management strategies for VAD recipients with MDRO colonization given this increased risk.